Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2012 - Documents - Presentations -
datadescriptionsizeautor dokument 
04.05.26Stem cells for basic research on HD32 kBanonymousapplication/msword
04.05.26Stem cells for basic research on HD32 kBanonymousapplication/msword
04.05.26Keynote presentations32 kBanonymousapplication/msword
04.05.26Post-translational modifications of huntingtin32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Updates on lowering huntingtin (htt) levels32 kBanonymousapplication/msword
04.05.26HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplasmic aggregation and rescues synaptic dysfunction in HD mouse models32 kBanonymousapplication/msword
04.05.26Sirt1-inhibition: SienaBiotech32 kBanonymousapplication/msword
04.05.26PDE-10-inhibition: Pfizer32 kBanonymousapplication/msword
04.05.26PDE-4-inhibition: GSK32 kBanonymousapplication/msword
04.05.26Htt lowering: Medtronic-Alnylam/Isis/CHDI32 kBanonymousapplication/msword
04.05.26Phenotyping neural networks in an ovine model of HD32 kBanonymousapplication/msword
04.05.26Aging pathway and poly-Q neurotoxicity32 kBanonymousapplication/msword
04.05.26NeuroNet and its potential for the study of neurodegeneration32 kBanonymousapplication/msword
04.05.26Behavioral assessment and management of behavioral issues32 kBanonymousapplication/msword
04.05.26Differential diagnosis of chorea32 kBanonymousapplication/msword
04.05.26Post-translational modifications and proteolysis of huntingtin32 kBanonymousapplication/msword
04.05.26Advanced HD Working Group32 kBanonymousapplication/msword
04.05.26Animal studies on the effects of physiotherapy32 kBanonymousapplication/msword
04.05.26RNA toxicity in poly-Q disorders32 kBanonymousapplication/msword
04.05.26Longevity pathways and their relevance to human disease32 kBanonymousapplication/msword
04.05.26Frequency of Huntington Disease - Greater than you think32 kBanonymousapplication/msword
04.05.26What are we really looking for in an HD drug?32 kBanonymousapplication/msword
04.05.26Care, coping and research in HD – the earlier the better!32 kBanonymousapplication/msword
04.05.26Human physiotherapy studies32 kBanonymousapplication/msword
04.05.26Default-mode network changes in preclinical Huntington´s disease32 kBanonymousapplication/msword
04.05.26Cognitive alterations in HD32 kBanonymousapplication/msword
04.05.26Lessons of the day32 kBanonymousapplication/msword
04.05.26Clinical management of Huntington’s disease32 kBanonymousapplication/msword
04.05.26Update on stem cell research: clinical potentials32 kBanonymousapplication/msword
04.05.26Critical consideration of the criteria for the motor diagnosis of HD32 kBanonymousapplication/msword
04.05.26Longitudinal functional and connectivity changes during working memory performance in HD32 kBanonymousapplication/msword
04.05.26Better global and cognitive functioning for choreatic compared to hypokinetic- rigid HD32 kBanonymousapplication/msword
04.05.26Bupropion: ACTION-HD32 kBanonymousapplication/msword
04.05.26Overview of CHDI drug development programs32 kBanonymousapplication/msword
04.05.26Drug discovery and development process32 kBanonymousapplication/msword
04.05.26Lessons of the day32 kBanonymousapplication/msword
04.05.26Standards of Care32 kBanonymousapplication/msword
04.05.26EHDN Update - EC elections, SBAC elections, Structure of EHDN32 kBanonymousapplication/msword
04.05.26Dopaminergic stabilization in HD: pridopidine32 kBanonymousapplication/msword
04.05.26Reach2HD PBT232 kBanonymousapplication/msword
04.05.26PREQUEL EHDN32 kBanonymousapplication/msword
04.05.26Juvenile Huntington's disease32 kBanonymousapplication/msword
04.05.26Default-mode network changes in preclinical Huntington’s disease32 kBanonymousapplication/msword
04.05.26New assessment tools (cognitive batteries)32 kBanonymousapplication/msword
04.05.26Poster Awards32 kBanonymousapplication/msword
04.05.26REGISTRY and Enroll-HD32 kBanonymousapplication/msword
04.05.26Better global and cognitive functioning for choreatic compared to hypokinetic-rigid Huntington’s disease32 kBanonymousapplication/msword
04.05.26Progress in HD research and HD advocacy: a personal view32 kBanonymousapplication/msword
04.05.26Juvenile HD Working Group32 kBanonymousapplication/msword
04.05.26MRI as a potential marker for HD32 kBanonymousapplication/msword
04.05.26Defining predictors of disease32 kBanonymousapplication/msword
04.05.26Presentation of the HDYO website32 kBanonymousapplication/msword
04.05.26Huntingtin32 kBanonymousapplication/msword
04.05.26Falling in love, staying in love32 kBanonymousapplication/msword
04.05.26Defining predictors of disease32 kBanonymousapplication/msword
04.05.26Critical consideration of the criteria for the motor diagnosis of Huntington disease32 kBanonymousapplication/msword
04.05.26New assessment tools (cognitive batteries)32 kBanonymousapplication/msword
04.05.26Brain imaging as a potential marker for HD (PET)32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Scientific strategy of EHDN32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Training on HD assessments including HD-CC32 kBanonymousapplication/msword
04.05.26Common issues/problems/inconsistencies in HD assessments32 kBanonymousapplication/msword
04.05.26HD for Basic Scientists32 kBanonymousapplication/msword
11.04.13Plenary Session I: ‘A look ahead’33blankintext/x-cms-note
11.04.13Plenary Session II: ‘Frontiers in biology and their relevance to Huntington’s disease’ 33blankintext/x-cms-note
11.04.13Plenary Session III: ‘Science practice at EHDN’ 33blankintext/x-cms-note
11.04.13Short Communications I: 'Scientific Presentations: 10’ and 5’ questions – selected from submissions' 33blankintext/x-cms-note
11.04.13Plenary Session IV: Keynote presentations33blankintext/x-cms-note
11.04.13Roundup I33blankintext/x-cms-note
11.04.13Breakfast teaching courses Sat33blankintext/x-cms-note
11.04.13Plenary Session V: ‘Understanding and manipulating the pathogenic process in Huntington’s disease’ 33blankintext/x-cms-note
11.04.13Plenary Session VI: Keynote presentations33blankintext/x-cms-note
11.04.13Short communications II: Scientific presentations33blankintext/x-cms-note
11.04.13Plenary Session VII: ‘Therapeutic development programs in Huntington’s Disease’33blankintext/x-cms-note
08.04.13Plenary Session VIII: EHDN Business Meeting33blankintext/x-cms-note
08.04.13Roundup II33blankintext/x-cms-note
08.04.13Breakfast teaching courses Sun33blankintext/x-cms-note
08.04.13Plenary Session IX: ‘Tools and outcome to monitor disease progression and response to therapy’33blankintext/x-cms-note
08.04.13Roundup III33blankintext/x-cms-note
08.04.13EHA meeting33blankintext/x-cms-note
08.04.13Oral Presentations33blankintext/x-cms-note

Folder contains 87 dokumenty.